Premium
Enriching cancer pharmacology with drugs of marine origin
Author(s) -
Jimenez Paula C.,
Wilke Diego V.,
Branco Paola C.,
Bauermeister Anelize,
RezendeTeixeira Paula,
Gaudêncio Susana P.,
CostaLotufo Leticia V.
Publication year - 2020
Publication title -
british journal of pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.432
H-Index - 211
eISSN - 1476-5381
pISSN - 0007-1188
DOI - 10.1111/bph.14876
Subject(s) - eribulin , medicine , trabectedin , cancer drugs , pharmacology , cancer , cancer therapy , clinical trial , drug , bioinformatics , oncology , breast cancer , biology , sarcoma , metastatic breast cancer , pathology , soft tissue sarcoma
Marine natural products have proven, over the last half‐century, to be effective biological modulators. These molecules have revealed new targets for cancer therapy as well as dissimilar modes of action within typical classes of drugs. In this scenario, innovation from marine‐based pharmaceuticals has helped advance cancer chemotherapy in many aspects, as most of these are designated as first‐in‐class drugs. Here, by examining the path from discovery to development of clinically approved drugs of marine origin for cancer treatment—cytarabine (Cytosar‐U®), trabectedin (Yondelis®), eribulin (Halaven®), brentuximab vedotin (Adcetris®), and plitidepsin (Aplidin®)— together with those in late clinical trial phases—lurbinectedin, plinabulin, marizomib, and plocabulin—the present review offers a critical analysis of the contributions given by these new compounds to cancer pharmacotherapy.